Stefansdottir Andrea B, Vieira Luis, Johnsen Arni, Isacson Daniel, Rodriguez Andres, Mani Maria
Department of Plastic and Reconstructive Surgery, Uppsala University Hospital, Uppsala, Sweden.
Department of Surgical Sciences, Uppsala University, Uppsala, Sweden.
Arch Plast Surg. 2024 Feb 29;51(2):156-162. doi: 10.1055/s-0043-1777673. eCollection 2024 Mar.
Perioperative management in autologous breast reconstruction has gained focus in recent years. This study compares two pain management protocols in patients undergoing abdominal-based free flap breast reconstruction: a past protocol (PP) and a current protocol (CP)-both intended to reduce opioid consumption postoperatively. The PP entails use of a pain catheter in the abdominal wound and the CP consists of an intraoperative nerve block in addition to refinements in the oral pain management. We hypothesize that the CP reduces opioid consumption compared to PP. From December 2017 to January 2020, 102 patients underwent breast reconstruction with an abdominal-based free flap. Two postoperative pain management strategies were used during the period; from December 2017 to September 2018, the PP was used which entailed the use of a pain catheter with ropivacaine applied in the abdominal wound with continuous distribution postoperatively in addition to paracetamol orally and oxycodone orally pro re nata (PRN). From October 2018 to January 2020, the CP was used. This protocol included a combination of intraoperative subfascial nerve block and a postoperative oral pain management regime that consisted of paracetamol, celecoxib, and gabapentin as well as oxycodone PRN. The CP group ( = 63) had lower opioid consumption compared to the PP group ( = 39) when examining all aspects of opioid consumption, including daily opioid usage in morphine milligram equivalents and total opioid usage during the stay ( < 0.001). The CP group had shorter length of hospital stay (LOS). Introduction of the CP reduced opioid use and LOS was shorter.
近年来,自体乳房重建的围手术期管理受到了关注。本研究比较了接受腹部游离皮瓣乳房重建患者的两种疼痛管理方案:过去的方案(PP)和当前的方案(CP)——两者都旨在减少术后阿片类药物的使用。PP包括在腹部伤口使用止痛导管,而CP除了优化口服疼痛管理外,还包括术中神经阻滞。我们假设与PP相比,CP能减少阿片类药物的使用。
2017年12月至2020年1月,102例患者接受了腹部游离皮瓣乳房重建。在此期间使用了两种术后疼痛管理策略;2017年12月至2018年9月,使用PP,即除口服对乙酰氨基酚和按需口服羟考酮外,在腹部伤口使用含罗哌卡因的止痛导管并在术后持续给药。2018年10月至2020年1月,使用CP。该方案包括术中筋膜下神经阻滞与术后口服疼痛管理方案相结合,后者由对乙酰氨基酚、塞来昔布、加巴喷丁以及按需使用的羟考酮组成。
在检查阿片类药物使用的所有方面时,包括以吗啡毫克当量计算的每日阿片类药物使用量和住院期间的总阿片类药物使用量,CP组(n = 63)的阿片类药物使用量低于PP组(n = 39)(P < 0.001)。CP组的住院时间较短。
CP的引入减少了阿片类药物的使用,且住院时间更短。